ai3Bio Targets T Cells to Tackle Autoimmune Diseases

Introducing ai3Bio

Biotech startup ai3Bio has recently emerged from stealth mode, boasting an impressive $48 million in Series A funding. The company aims to revolutionize the treatment of autoimmune diseases by addressing what they see as the root cause: dysfunctional T cells.

Founded by Dr. Steven Altschuler and scientist Jonathan Kagan, ai3Bio’s mission is clear. "We focus solely on eliminating diseased T cells," Kagan explains.

The Problem with Current Treatments

T cells play a major role in autoimmune diseases, mistakenly attacking healthy tissue instead of harmful pathogens. Despite this knowledge being established over three decades ago, there have been limited advancements in effectively targeting these rogue cells. Kagan points out the shortcomings of today’s therapies, stating, "While these drugs generate substantial revenue, they don’t truly solve the underlying issues of autoimmune diseases. Many of them merely manage symptoms rather than targeting the problem directly."

Innovative Approaches to Treatment

ai3Bio has developed two key strategies for combating autoimmune conditions. The first is called T Deplete, a monoclonal antibody designed to eliminate inflammatory T cells while protecting healthy ones. The second, known as STARx (Selective T cell Apoptosis Therapy), utilizes lipid nanoparticles to deliver mRNA to Th17 cells, prompting those problematic cells to self-destruct.

This approach represents a shift in the autoimmune treatment landscape. Existing therapies typically focus on neutralizing cytokines produced by T cells, such as IL-17, which drive inflammation and tissue damage. Kagan emphasizes that it’s insufficient to simply target cytokines: "That’s akin to catching bullets after they’ve been fired instead of disarming the gun. We want to remove those T cells that create these cytokines in the first place."

Market Potential and Future Directions

According to Kagan, the market for autoimmune treatments has exceeded $130 billion, highlighting a significant opportunity for new methodologies. Ai3Bio is particularly interested in treating inflammatory arthritis, including ankylosing spondylitis, and addressing autoimmune liver diseases—areas with dire need for effective therapies.

Dr. Altschuler believes that therapies focusing on these diseases have multi-billion dollar market potential. "For ankylosing spondylitis alone, we see a market estimated around $7 billion," he notes, targeting patients who haven’t benefited from existing treatments.

The next steps for ai3Bio include advancing their IND-enabling studies for the antibody approach, anticipating to file for an Investigational New Drug (IND) application by late 2027, and initiating human trials thereafter.

Standing Out in a Competitive Landscape

While chronic competition exists within the autoimmune treatment arena—with other companies like AbbVie and Amgen also exploring therapies—ai3Bio aims to distinguish itself with its straightforward technology and unique focus on T cells. The startup is leveraging artificial intelligence to refine its strategies and identify specific markers on problematic T cells, simplifying the development process.

As ai3Bio progresses, it hopes that its innovative tactics can lead to meaningful advancements in the treatment of autoimmune diseases, moving from merely managing symptoms to targeting and eliminating the underlying causes.

“The gun is the T cell, and the bullet is IL-17.” - Jonathan Kagan